Chemotherapy for gastric carcinoma: New and old options

ONCOLOGY

Volumn 12, Issue 10 SUPPL. 7, 1998, Pages 44-47

  Ajani, Jaffer A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; CAPECITABINE; DOCETAXEL; DOXORUBICIN; ENZYME INHIBITOR; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN; PACLITAXEL; TEGAFUR; UFT; URACIL; URACIL DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG ABSORPTION; DRUG ACTIVITY; DRUG METABOLISM; DRUG MIXTURE; DRUG RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PALLIATIVE THERAPY; QUALITY OF LIFE; STOMACH CARCINOMA;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DEOXYCYTIDINE; DRUG COMBINATIONS; ENZYME INHIBITORS; ETOPOSIDE; HUMANS; INFUSIONS, INTRAVENOUS; OXONIC ACID; PACLITAXEL; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; STOMACH NEOPLASMS; TAXOIDS; TEGAFUR; URACIL;

EID: 0031731267     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. Ca Cancer J Clin 48:6-29, 1998.
2. Philip PA, Ajani JA: Gastric carcinoma, in Pazdur R (ed): Medical Oncology: A Comprehensive Review, 2nd ed, pp 235-246. Huntington, NY, PRR, 1996.
3. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993.
4. Pyrhonen S, Kuitunen T, Kouri M: A randomized, phase III trial comparing fluorouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer (abstract 6). Ann Oncol 3:12(suppl), 1992.
5. Glimelius B, Hoffmann K, Haglund U, et al: Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol 5:189-190, 1994.
6. Scheithauer W, Komek G, Zeh B, et al: Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer. A randomized trial (abstract). Second International Conference on Biology, Prevention, and Treatment of GI Malignancy, p 68. Koln, Germany, 1995.
7. Comis S: Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1:221-238, 1974.
8. Kelsen DP, Magill G, Cheng E, et al: Phase II trial of etoposide (VP-16) in the treatment of upper gastrointestinal malignancies. Proc Am Soc Clin Oncol 1:96, 1982.
9. Lacave A, Izarzugaza I, Aparicio L, et al: Phase II clinical trial of cisdichlorodiammineplatinum in gastric cancer. Am J Clin Oncol 6:35-38, 1983.
10. Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin. JAMA 253:2061-2067, 1985.
11. Wils JA, Klein HO, Wagener DJ, et al: FAMTX (5-FU, Adriamycin and melhotrexate): A step ahead in the treatment of advanced gastric cancer: A Trial of the European Organization for Research and Treatment of Cancer of the Gastrointestinal Tract Cooperative Group. J Clin Oncol 9:827-831, 1991.
12. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophasogastric cancer. J Clin Oncol 15:261-167, 1997.
13. Wilke H, Wils J, Rougier P, et al: Preliminary analysis of a randomized phase III trial of FAMTX vs. ELF vs. Cisplatin/FU in advanced gastric cancer. Proc Am Soc Clin Oncol 14:206, 1995.
14. Ajani JA, Ilson DH, Daugherty K, et al: Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086-1091, 1994.
15. Ajani JA, Fairweather J, Dumas P, et al: Phase II study of Taxol in patients with gastric carcinoma. Cancer J Sci Am 4(4):269-274, 1998.
16. Einzig AI, Lipsitz S, Wiernik PH, et al: Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract: The Eastern Cooperative Oncology Group (ECOG) Results. Invest New Drugs 13:223-227, 1995.
17. Tamura F, Ohtsu A, Boku N, et al: Three-hour infusion of paclitaxel for advanced gastric cancer. Proc Am Soc Clin Oncol 16:307a, 1997.
18. Kim JS, Shin SW, Kim JH, et al: A phase II trial of Taxol, cisplatin, and 5-fluorouracil in patients with advanced gastric carcinoma (AGC). Cancer, 1998 (in press).
19. Taguchi T: A late phase II study of docetaxel in patients with gastric cancer. Proc Am Soc Clin Oncol 16:263a, 1997.
20. Sulkes A, Smyth J, Sessa C, et al: Docetaxel in advanced gastric cancer. Results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 70:380-383, 1994.
21. Einzig AI, Newberg D, Remick SC, et al: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncology 13:87-93, 1996.
22. Roth AD, Maibach R, Martinelli G, et al: Taxotere-cisplatin in advanced gastric carcino-ma: An active drug combination. Proc Am Soc Clin Oncol 17:283a, 1998 (abstract No. 1088).
23. Kambe M, Wakui A, Nakao I, et al: A late phase II study of irinotecan (CPT-11) in patients with advanced gastric cancers (abstract). Proc Am Soc Clin Oncol 12:198, 1993.
24. Shirao K, Shimada Y, Kondo H, et al: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 15:921-927, 1997.
25. Boku N, Ohtsu A, Shimada Y, et al: Phase II study of a combination of CDDP and CPT-II in metastatic gastric cancer: CPT-11 Study Group for Gastric Cancer (abstract No. 936). Proc Am Soc Clin Oncol 16:264a, 1997.
26. Enzinger PC, IIson DH, Saltz LB, et al: A phase II trial of cisplatin and irinotecan in patients with advanced esophageal carcinoma (abstract no. 1085). Proc Am Soc Clin Oncol 17:282a, 1998.
27. Slevin ML: Low-dose oral etoposide: A new role for an old drug? J Clin Oncol 8:1607-1609, 1990 (editorial).
28. Ajani JA, Mansfield PM, Dumas P: Oral etoposide for patients with advanced gastric carcinoma. Cancer J Sci Am. 1998 (in press).
29. Pazdur R, Covington WP, Brown NS, et al: Comparative steady state pharmacokinetics of oral UFT versus protracted intravenous 5-fluorouracil (FU) (abstract 1498). Proc Am Soc Clin Oncol 15:474, 1996.
30. Namatame K, Sasaki E, Takeda S, et al: A double-blind comparison of FUra plasma concentration by oral (UFT) vs continuous intravenous infusion (5-FU). Jap J Cancer Chemother 20:2417-2419, 1993.
31. Takiuchi T, Ajani JA: UFT in gastric cancer: A comprehensive review. J Clin Oncol 16:2877-2885, 1998.
32. Ohtsu A, Sakata M, Horikoshi N, et al: A phase II study of S-1 in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 17:262a, 1998 (abstract no. 1005).
33. Kurihara M, Koizumi W, Hasegawa K, et al: Late phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with advanced gastric cancer. Proc Am Soc Clin Oncol 17:262a, 1998 (abstract no. 1007).
34. Humerickhouse RA, Schilsky RL: Thymidylate synthase inhibitors in clinical development. Cancer Therapeutics 1:100-113, 1998.
35. DeMario MD, Ratain MJ: Oral chemotherapy. Rationale and future directions. J Clin Oncol 16:2557-2567, 1998.